Clinical Trials Logo

Neuroendocrine Tumor Grade 2 clinical trials

View clinical trials related to Neuroendocrine Tumor Grade 2.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04789109 Recruiting - Liver Metastases Clinical Trials

CapTem Plus Radioembolization for NET Liver Metastases

CapTemY90
Start date: November 2021
Phase: Phase 2
Study type: Interventional

Grade 2 neuroendocrine tumors have an intermediate rate of progression following embolotherapy of liver metastases. The combination of capecitabine and temozolomide has been shown to be an active regimen in this disease. Both drugs are radiosensitizers, and in a safety and feasibility study were combined with yttrium-90 radioembolization with acceptable additive toxicities and better than expected response and duration of disease control. This study expands use of this regimen in a Phase 2 investigation to confirm efficacy of the integrated chemoradiation technique.

NCT ID: NCT04464122 Recruiting - Clinical trials for Neuroendocrine Tumors

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

REBORN
Start date: September 14, 2020
Phase:
Study type: Observational

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

NCT ID: NCT04339036 Recruiting - Clinical trials for Neuroendocrine Tumors

CapTemY90 for Grade 2 NET Liver Metastases

CapTemY90
Start date: October 7, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.